SK Biopharmaceuticals Co., Ltd. (KRX: 326030)
South Korea
· Delayed Price · Currency is KRW 103,300
-200 (-0.19%)
Nov 15, 2024, 3:30 PM KST
SK Biopharmaceuticals Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 465,064 | 354,892 | 246,179 | 418,645 | 25,999 | 123,852 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | - | - | Upgrade
|
| Revenue | 465,064 | 354,892 | 246,179 | 418,645 | 25,999 | 123,852 | Upgrade
|
| Revenue Growth (YoY) | 60.70% | 44.16% | -41.20% | 1510.23% | -79.01% | 11172.24% | Upgrade
|
| Cost of Revenue | 41,461 | 34,082 | 37,768 | 22,336 | 1,974 | 514.2 | Upgrade
|
| Gross Profit | 423,603 | 320,809 | 208,411 | 396,309 | 24,025 | 123,338 | Upgrade
|
| Selling, General & Admin | 208,973 | 204,313 | 201,258 | 172,875 | 142,443 | 22,539 | Upgrade
|
| Research & Development | 156,581 | 137,126 | 122,817 | 114,526 | 108,441 | 176,213 | Upgrade
|
| Other Operating Expenses | 4,937 | 4,458 | 3,855 | 3,692 | 3,134 | 76.17 | Upgrade
|
| Operating Expenses | 383,192 | 358,331 | 339,489 | 301,350 | 263,524 | 202,597 | Upgrade
|
| Operating Income | 40,411 | -37,522 | -131,078 | 94,958 | -239,499 | -79,259 | Upgrade
|
| Interest Expense | -9,992 | -8,280 | -3,717 | -946.98 | -4,462 | -1,547 | Upgrade
|
| Interest & Investment Income | 10,092 | 9,317 | 6,755 | 2,343 | 2,121 | 1,783 | Upgrade
|
| Earnings From Equity Investments | -26,228 | -11,535 | -14,927 | -83,813 | - | -4,974 | Upgrade
|
| Currency Exchange Gain (Loss) | 4,226 | 1,026 | 8,878 | 11,985 | 494.22 | 2,094 | Upgrade
|
| Other Non Operating Income (Expenses) | 487.37 | -2,281 | -5,338 | -4,724 | -550.24 | -540.87 | Upgrade
|
| EBT Excluding Unusual Items | 18,996 | -49,274 | -139,427 | 19,803 | -241,896 | -82,444 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2,893 | 12,243 | -2,858 | 51,477 | 1,987 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 162.25 | -18.72 | -11.28 | -3.02 | -0.29 | -2,007 | Upgrade
|
| Asset Writedown | -6,808 | -6,808 | -172.96 | - | - | - | Upgrade
|
| Pretax Income | 15,243 | -43,858 | -142,469 | 71,277 | -239,909 | -84,451 | Upgrade
|
| Income Tax Expense | -9,345 | -8,478 | -3,038 | 6,431 | 7,504 | -12,932 | Upgrade
|
| Earnings From Continuing Operations | 24,588 | -35,379 | -139,431 | 64,846 | -247,414 | -71,519 | Upgrade
|
| Net Income to Company | 24,588 | -35,379 | -139,431 | 64,846 | -247,414 | -71,519 | Upgrade
|
| Minority Interest in Earnings | 9,209 | 2,497 | - | - | - | - | Upgrade
|
| Net Income | 33,796 | -32,883 | -139,431 | 64,846 | -247,414 | -71,519 | Upgrade
|
| Net Income to Common | 33,796 | -32,883 | -139,431 | 64,846 | -247,414 | -71,519 | Upgrade
|
| Shares Outstanding (Basic) | 78 | 78 | 78 | 78 | 72 | 65 | Upgrade
|
| Shares Outstanding (Diluted) | 78 | 78 | 78 | 78 | 72 | 65 | Upgrade
|
| Shares Change (YoY) | - | - | - | 9.12% | 10.41% | 4.42% | Upgrade
|
| EPS (Basic) | 431.55 | -419.89 | -1780.43 | 828.03 | -3447.52 | -1100.30 | Upgrade
|
| EPS (Diluted) | 431.11 | -419.89 | -1780.43 | 828.03 | -3447.52 | -1100.30 | Upgrade
|
| Free Cash Flow | -8,038 | -96,586 | -164,831 | -97,188 | -221,749 | -94,534 | Upgrade
|
| Free Cash Flow Per Share | -102.64 | -1233.33 | -2104.77 | -1241.01 | -3089.90 | -1454.38 | Upgrade
|
| Gross Margin | 91.08% | 90.40% | 84.66% | 94.66% | 92.41% | 99.58% | Upgrade
|
| Operating Margin | 8.69% | -10.57% | -53.24% | 22.68% | -921.18% | -63.99% | Upgrade
|
| Profit Margin | 7.27% | -9.27% | -56.64% | 15.49% | -951.63% | -57.75% | Upgrade
|
| Free Cash Flow Margin | -1.73% | -27.22% | -66.96% | -23.21% | -852.91% | -76.33% | Upgrade
|
| EBITDA | 57,544 | -22,205 | -118,094 | 106,600 | -228,640 | -72,758 | Upgrade
|
| EBITDA Margin | 12.37% | -6.26% | -47.97% | 25.46% | - | -58.75% | Upgrade
|
| D&A For EBITDA | 17,132 | 15,317 | 12,984 | 11,642 | 10,859 | 6,501 | Upgrade
|
| EBIT | 40,411 | -37,522 | -131,078 | 94,958 | -239,499 | -79,259 | Upgrade
|
| EBIT Margin | 8.69% | -10.57% | -53.24% | 22.68% | - | -63.99% | Upgrade
|
| Effective Tax Rate | - | - | - | 9.02% | - | - | Upgrade
|
| Advertising Expenses | - | 38,926 | 48,476 | 38,775 | 24,706 | 53.53 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.